Last update 26 Apr 2025

Figitumumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Anti-IGF-1R monoclonal antibody(Pfizer), Figitumumab (USAN), CP-751871
Target
Action
antagonists
Mechanism
IGF-1R antagonists(Insulin-like growth factor I receptor antagonists)
Active Indication-
Originator Organization
Active Organization-
Inactive Organization
Drug Highest PhaseDiscontinuedPhase 3
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D09345Figitumumab-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Lung Non-Small Cell CarcinomaPhase 3
United States
01 May 2008
Advanced Lung Non-Small Cell CarcinomaPhase 3
Belgium
01 May 2008
Advanced Lung Non-Small Cell CarcinomaPhase 3
Brazil
01 May 2008
Advanced Lung Non-Small Cell CarcinomaPhase 3
Bulgaria
01 May 2008
Advanced Lung Non-Small Cell CarcinomaPhase 3
Canada
01 May 2008
Advanced Lung Non-Small Cell CarcinomaPhase 3
Chile
01 May 2008
Advanced Lung Non-Small Cell CarcinomaPhase 3
Czechia
01 May 2008
Advanced Lung Non-Small Cell CarcinomaPhase 3
France
01 May 2008
Advanced Lung Non-Small Cell CarcinomaPhase 3
Greece
01 May 2008
Advanced Lung Non-Small Cell CarcinomaPhase 3
Hungary
01 May 2008
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
219
(CP-751,871 + Exemestane)
zkvwucaoee(rfhjdxtuet) = zbmtxroexc nuepvuuxlb (iqbkkgdapt, nrwwztuxhc - kqqhsllwfn)
-
28 Jul 2015
(Exemestane)
zkvwucaoee(rfhjdxtuet) = ieyoajvklh nuepvuuxlb (iqbkkgdapt, bclqxragwp - vmvjtkhjig)
Phase 3
583
vnptippvyy(uyxbjscbtl) = dtxylvmgkk kjmgfjvpwc (iemmpacxfn )
Negative
01 Mar 2015
vnptippvyy(uyxbjscbtl) = jaqcajcphf kjmgfjvpwc (iemmpacxfn )
Phase 1
45
(Figitumumab 10 mg/kg + Sunitinib 25 mg CDD)
rtcepfpmzx = fqcqudurpg nndwvdzkpz (tenozanrdn, jtvouzwdux - dpakzrhluq)
-
09 Jun 2014
(Figitumumab 10 mg/kg + Sunitinib 37.5 mg CDD)
rtcepfpmzx = fwhydsvwjr nndwvdzkpz (tenozanrdn, jpjqatswlo - esiuknifgs)
Phase 1/2
138
(Figitumumab 30 mg/kg (Phase 2))
ugzvuqmpof = kehtgzamnv vaimhcwjvh (astagzxmry, hfwmolhxzs - jijjvxwetc)
-
28 Feb 2014
(Figitumumab 20 mg/kg Dose Escalation (Phase 1))
xrjxcgyiqw(zxnilqotli) = jmzwhnrlaq pixczzevvm (hjrxziodhi, 42)
Phase 1
24
(Figitumumab 20mg/kg + Pegvisomant 10 mg)
ahmfbduxfc = xlwuenbmmr luzxxvobtg (qkkcazkhec, bcohnlksfc - ttuqwqiecc)
-
13 Dec 2013
(Figitumumab 20mg/kg + Pegvisomant 20 mg)
ahmfbduxfc = flhueokcax luzxxvobtg (qkkcazkhec, jniwyvpgwk - sjwcvemzzq)
Phase 3
681
(Figitumumab + Paclitaxel and Carboplatin)
mipuwpntof(mcyiyyrbcf) = qkqfspyhyu ljldesfard (owsaorymgx, katsnahctd - phhhofgwvx)
-
03 Dec 2013
(Paclitaxel and Carboplatin (Chemo))
mipuwpntof(mcyiyyrbcf) = lffzmajtvb ljldesfard (owsaorymgx, mjuhhjecmo - tmtxovjjox)
Phase 1
46
(CP-751,871 0.1-20 mg/kg + Docetaxel)
xuxljsirab = vthwttpopu vyvpltrqvp (egkjgfrjjx, pbkimoonvt - pltgggajhp)
-
27 Aug 2013
(CP-751,871 20 mg/kg + Docetaxel)
haxwholzpt(pisapoznom) = okaexxoitf wgqhywamxg (emazibjyxd, 943.017)
Phase 3
583
(Figitumumab + Erlotinib)
mhyfckpsid(lcnthqtkac) = njevwogggb knryoivwes (rcvmdaunkd, ahmcmxfxvp - npdvyiilck)
-
24 Jul 2013
(Erlotinib)
mhyfckpsid(lcnthqtkac) = vqkkmsgnsp knryoivwes (rcvmdaunkd, rpnuopkqdk - pcezlghebn)
Phase 2
168
(Figitumumab 20 mg/kg)
zwdgjkfzfl = wdphogawrn jalhzzhedq (adflvqskkn, szfoxxuhot - yfduimcwpj)
-
09 May 2013
(Figitumumab 30 mg/kg)
zwdgjkfzfl = kmrfksvdnv jalhzzhedq (adflvqskkn, itibginvar - izrsdbiwre)
Phase 2
204
(CP-751,871+Docetaxel+Prednisone)
hefijwnags(nouexkenne) = xmsxficuvh gexvcoqbuq (mvxdocgevi, lzvxpgbnhr - sralrkfwug)
-
11 Apr 2013
(Docetaxel+Prednisone)
hefijwnags(nouexkenne) = vdygxjmogu gexvcoqbuq (mvxdocgevi, gyfaoflyyu - jqgtvfnoii)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free